Comparing IV and oral hydration to prevent kidney injury after CT scans in severe kidney disease patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial evaluates the effectiveness of intravenous (IV) hydration versus oral hydration in preventing post-contrast acute kidney injury (PC-AKI) in patients with severe chronic kidney disease (CKD) scheduled for elective contrast-enhanced computed tomography (CECT). It is a pragmatic, single-centre, open-label, parallel-group non-inferiority randomized controlled trial conducted at Odense University Hospital. Participants will be randomly assigned to receive either IV hydration or oral hydration before and after the CECT procedure. The study aims to determine if oral hydration can be as effective as the standard IV hydration protocol recommended for high-risk patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* eGFR \< 30 mL/min/1.73 m2
* Scheduled for elective IV CECT
* Age ≥ 18
* Signed informed consent

Exclusion Criteria:

* Allergy to Iodine
* Pregnancy
* Active dialysis treatment
* Acute infectious or inflammatory disease
* Acute pre- and/or post-renal kidney failure
* Unable to understand study information

Where it's running

• Department of Cardiology
  Odense C, Fyn, Denmark Recruiting

Study contacts

• Study coordinator: Kristian Altern Øvrehus, Chief physician
• Email: kristian.altern.ovrehus@rsyd.dk
• Phone: +45 28305454

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Golcadomide pharmacokinetics and safety in severe kidney impairment and ESRD

  This study tests how golcadomide behaves in the body and whether it is safe in adults with severe kidney problems or end-stage kidney disease, compared with people with normal kidney function.

  Recruiting at 3 sites Phase 1 Bristol-Myers Squibb · Chandler, Arizona and 2 other locations · NCT07763418

• Digital Prevention Platform for Lifelong Health

  A digital health platform, DELPHI, will test personalized prevention tips for healthy adults aged 18-65 to see if it improves well-being over 12 months.

  Recruiting Istituto per la Ricerca e l'Innovazione Biomedica · Messina · NCT07612852

• Immune Reset to Enable Kidney Transplant for Highly Sensitized Patients

  This study tests whether a temporary immune system reboot using a patient’s own stem cells can help highly sensitized kidney patients receive a compatible transplant.

  Recruiting Phase 1/2 Hospital Universitari Vall d'Hebron Research Institute · Barcelona, Catalonia · NCT07607197

• Oral versus IV hydration to prevent contrast-related kidney injury after CT in the ER

  This trial will test whether drinking water works as well as intravenous saline to prevent contrast-related kidney injury in adults with reduced kidney function who need a contrast CT in the emergency department.

  Recruiting Gaziosmanpasa Research and Education Hospital · Istanbul, Gaziosmanpasa · NCT07459413

• Venetoclax added to reduced-intensity conditioning for combined stem cell and kidney transplant

  This trial tests whether adding venetoclax to a reduced-intensity conditioning regimen is safe for adults with blood cancers who are receiving a combined stem cell and kidney transplant from a matched or partially matched donor.

  Recruiting Early Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT07358195

• See if extra caffeine helps preterm babies with kidney oxygen problems

  This study tests whether giving additional caffeine to very premature babies with low kidney oxygen levels can improve kidney health without harming the brain.

  Recruiting Phase 2 University of Wisconsin, Madison · Madison, Wisconsin · NCT07262060

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.